Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: Dato-DXd with or without osimertinib versus platinum chemotherapy in EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib
CTR20244119Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, osimertinib, pemetrexed, cisplatin, carboplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244119.